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6.0 Introduction 
Kristina Åkesson, MD, PhD 
 
Department of Clinical Sciences, Lund University, Malmö, Sweden; Clinical and Molecular 
Osteoporosis Research Unit, Skåne University Hospital, Malmö, Sweden. 
 
 
Over recent decades, the many advances in science and technology have changed what is possible to 
achieve and how it can be achieved. 
At the same time, our expectations and needs have changed, moving towards person-centered care and 
shared decision making. The global burden of disease has also shifted, with an increase in non-
communicable diseases many of which are now chronic. 
Beyond this are demographic changes, with proportionally more people living well into old age. Even 
if the majority remain healthy, this still represents a substantial musculoskeletal health risk with 
functional limitations throughout the life course.  This includes the areas of back pain, joint diseases and 
fractures. This also leads to increasing demands on the health care systems and costs to the economy, 
warranting changes in practice to find better ways of providing high value care. 
The use of innovations and trend toward digital solutions however, needs to be monitored in order not 
to distort delivery of care, which could decrease the opportunity for equity of care. 
How are these needs and opportunities reflected in MSK care? In this chapter we give a series of case 
studies, highlighting the advantages, gaps and challenges.
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6.1 Low back pain 
 
Rachelle Buchbinder AO MBBS (Hons) MSc PhD FRACP FAHMS 
 
 
Low back pain remains the leading cause of disability globally and in most countries of the world. 
According to the latest Global Burden of Disease Project estimates, it contributes 42.5 million years 
lived with disability or 7.6% of the world’s disability burden [1]. This burden has increased by over 
50% since 1990, disproportionally affecting low- and middle-income countries [2]. Working-age groups 
are most affected, which means that the economic burden of low back pain is also enormous.  
Based upon studies performed in high-income countries these costs are also rising [2-4]. Low back pain 
accounts for the highest proportion of medically certified sick leave and early retirement in Europe [5]. 
Lower socioeconomic status and educational attainment are risk factors for both development of 
disabling low back pain and forced premature retirement due to chronic low back pain; contributing to 
social inequality and the poverty cycle [2, 6]. This is accentuated in poorer regions of the world where 
informal employment is common, there may be limited opportunities for modified work and there is 
non-existent or poorly managed occupational health and social support systems [2]. 
Despite these compelling data, global and national efforts to address the burden of low back pain remain 
suboptimal. As outlined in The Lancet series on low back pain, published in 2018 co-authored by 31 
authors from 12 countries, over-medicalisation of low back pain has led to health care that is not only 
ineffective but potentially harmful, and this is true across all income settings [2, 7, 8]. Pervasive low-
value practices include unnecessary imaging, care taking place in emergency settings, and liberal use of 
bed rest, electrotherapies, opioids, spine injections and surgery. Rather than declining, these practices 
are escalating in many parts of the world [9, 10]. 
There is a pervasive and deeply embedded culture that is resistant to de-medicalising the problem [8]. 
For example, despite consistent evidence to the contrary, the majority of patients believe imaging is 
necessary to get the best medical care for low back pain [11]. Many clinicians also believe this, 
particularly doctors with a self-reported special interest in low back pain [12]. Vested interests and 
perverse incentives that reinforce low-value care and discourage right care are rife, while fragmented 
and outdated models of care also contribute to the problem [9]. 
A harmonised systems approach that takes into account and addresses legal, administrative, social, 
political, clinical and cultural challenges is needed to address the burden of low back pain [9, 13, 14]. 
The Lancet call to action recommended that at the global level, the World Health Organization (WHO) 
should prioritise new public policies and urgent political action to ensure strategies are put in place to 
mitigate the global burden of low back pain as well as other musculoskeletal conditions [8]. Despite 
being among the most burdensome non-communicable diseases, only half of the Organisation for 
Economic Co-operation and Development member states make reference to musculoskeletal conditions 
[15]. Putting musculoskeletal health on the WHO target list could increase attention to these problems, 
and low back pain, together with other similar regional musculoskeletal conditions, should also be 
integrated into all chronic disease initiatives. 
Public health education approaches that aim to simultaneously modify knowledge and attitudes of a 
large proportion of the community continues to show potential. A recent systematic review of mass 
media campaigns that included 18 studies, all conducted in high-income countries, found positive and 
  5(32) 
persistent effects on both societal and healthcare provider beliefs [16]. While the results were mixed in 
terms of effects on disability behaviour and health utilisation, the largest benefits were observed 
following a well-funded Australian campaign; it used television advertisements as the primary medium, 
had almost universal awareness of the messaging, and was supported by policy and legislation that 
encouraged remaining at work [17, 18]. Creative use of digital and social media platforms, particularly 
in low- and middle-income countries, are promising new avenues for public health interventions. 
Underpinned by the available evidence, these should carefully consider the local cultural and regulatory 
environment and barriers to behaviour change, and the health and economic effects should be rigorously 
evaluated. 
Many health systems are not designed to optimise evidence-based care for low back pain [13]. Health 
systems and policy solutions that may address this include wiser use of funding and reimbursement 
drivers, more focused attention on implementation of best practice, reform of the education and training 
of health care professionals, better coordination between health and occupational care, and changes to 
clinical care pathways [7, 8, 13].  
One strategy receiving increased attention is to change the first health care provider that a patient with 
low back pain sees. Retrospective analyses of claims data have consistently found important differences 
between the care that is received, depending upon the initial healthcare provider [19-21]. Compared with 
initially being seen in primary care, seeing a physical therapist or chiropractor first reduced the risk of 
imaging, surgery, and both early and long-term opioid use [19, 20]. On the other hand compared with 
primary care, seeing a physical medicine specialist first increased risk of receiving radiographs and 
advanced imaging, injections and surgery [19], while being seen in emergency or acute care facilities 
increased the risk of early opioid prescription. Initial care by pain management, anesthesia or physical 
medicine and rehabilitation providers increased the risk of long-term opioid use [21]. Several studies 
have now found that physiotherapist-led direct referrals or screening and management of patients on 
orthopaedic waiting lists reduces waiting times and results in greater patient and referrer satisfaction 
[22, 23], however further data are needed to determine whether they also improve patient outcomes and 
are cost-effective or cost-saving in comparison with usual care.  
Some attempts to limit inappropriate imaging have met with success. For example, Baker et al reported 
a 37% reduction in x-ray requests by emergency physician doctors with use of a special requisition form 
[24], while a UK randomised trial of provision of short education messages on MRI reports reduced 
lumbar spine MRI requests by 23% [25]. Further trials are needed to determine whether changing the 
way in which imaging findings are reported, particularly the terminology used to describe age-related 
findings, likely of little clinical relevance, may also lead to less clinician and patient anxiety and the 
subsequent cascade of low value treatment.  
Based upon the premise that healthcare professionals lack the confidence or skills to deliver guideline 
concordant care of low back pain including advice about self-management, training programs have now 
been developed in various countries such as New Zealand, Ireland and Denmark with promising early 
results [26-29]. Clinician-led initiatives such as Choosing Wisely which aim to identify and reduce low-
value medical care have identified overuse of imaging for low back pain as a problem across many 
countries including the US, Canada, Italy, the Netherlands, Japan, Switzerland and Australia [30, 31], 
although as yet this has not translated in any significant decline in imaging rates [30, 32-34].  
The guiding principles of Choosing Wisely recommendations are that they should be within or 
significantly impact a particular health professional specialist domain of practice, thereby creating 
impetus for behavior change within that specific group as well as other groups within their sphere of 
influence. They are also required to be based upon compelling evidence for change. Governments could 
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be examining these recommendations and changing health policies to support or even compel change. 
For example, following a recent Choosing Wisely Australia recommendation made by the Australian 
Faculty of Pain Medicine that patients with low back pain should not be referred for spinal fusion surgery 
[35], the Australian government narrowed the indications for publicly subsidised spinal fusion [36]. 
However medical association lobbying that claimed this was an inappropriately restrictive change, led 
to a partial retraction of the changes, demonstrating some of the challenges with disinvestment.  
Another strategy that governments could employ is to conditionally approve new or unproven 
interventions pending evidence, as has been done in The Netherlands. For example, radiofrequency 
denervation for chronic back pain was conditionally approved, but later withdrawn when the Dutch 
government’s commissioned trial demonstrated it provided no added benefits over a standardised 
exercise program [37]. National Clinical Care Standards are a relatively recent scheme for reducing 
unwarranted variation in care that complement clinical practice guidelines. Designed to encourage 
implementation of guideline recommendations in health care settings regardless of location, Standards 
focus on a small number of critical evidence-practice gaps for a particular clinical condition. They 
comprise a brief list of ‘quality statements’ that outline the care that patients should expect to receive 
and are accompanied by ‘quality indicators’ that enable monitoring of the quality of care. To date, only 
the UK [38] and Ontario Canada [39] have developed Clinical Care Standards for low back pain, and 
their effects on care and patient outcomes have not yet been reported.   
There are many potential public health policy and health system solutions to the growing burden of 
disabling low back pain. While further evaluation of their effects is needed prior to their widespread 
application, political resolve will also be needed to realise large-scale improvements in medical care. 
Major challenges include the de-implementation and disinvestment from unhelpful practices, identifying 
the most cost-effective strategies for implementation of guideline-supported practice, and enforcing 
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6.2 Chronic MSK pain in LMIC  (low and middle income countries) (spine care program) 
Margareta Nordin Dr. Med. Sci, PT. 
 
 
Musculoskeletal pain and spine pain affect the low-and middle-income countries in a substantial way. 
Low back pain (non-specific) may lead to inability to work, leading to poverty and affects the wellbeing 
of the family and thereby the community. 
The largest increase in disability caused by low back pain in the past few decades have occurred in low- 
and middle-income countries.  In Asia, Africa, and the Middle East, most countries are constantly 
challenged by infectious diseases and are poorly equipped to deal with the growing burden of disability 
caused by back pain [40]. 
In 2017, the World Health Organization launched the Rehabilitation 2030 initiative, highlighting the 
growing unmet need for rehabilitation worldwide, as a result of health and demographic trends, and 
calling for coordinated action amongst all stakeholders to prevent disability through low cost initiative 
based on evidence (https://www.who.int/rehabilitation/rehab-2030-call-for-action/en/). 
In 2018 there was a call for change of paradigm for treatment of low back pain published in the Lancet 
and the European Spine Journal. These two large research groups; The Lancet Low Back Pain Series 
Working Group (3 publications) [2, 8] and the Global Spine Care Initiative (16 publications) [41, 42] 
pointed out the need for evidence based early treatment and a focus on prevention of disability for low 
back pain. 
In 2018 the World health Organization included musculoskeletal disease as a non-communicable disease 
as a priority for research and implementation of recommendations within the framework of the Basic 
Rehabilitation Package for the Health Workforce. These recommendations will be a World Health 
Organization resource that provides information on low-cost, high-impact and evidence-based 
interventions for rehabilitation that can be easily, safely and effectively delivered by existing workforce 
in primary health care and low-resource settings (https://www.who.int/rehabilitation/rehabilitation-
guide-for-action/en/). In 2020 the World Health Organization invited an expert group for low back pain 
to provide recommendations by spring 2021 and thereby offering a change of paradigm focused on 
evidence based care for low back pain in low- and middle-income countries. 
What will be the expected consequences? 
It is estimated that around 1, 2 billion individuals or about 15% of the global population are affected by 
disability worldwide and growing. People with disabilities have generally poorer health, lower education 
achievements, fewer economic opportunities, and higher rates of poverty than people without disabilities 
[42]. This is largely due to the lack of services available to them and the many obstacles they face in 
their everyday lives. Disability affects disproportionately the women, the elderly, the rural communities, 
and the lowest income population. There for a host of actions is necessary, such as universal healthcare, 
access to care through primary care providers. Low back pain is the number 1 cause of disability 
according to the Global Burden of Disease [40]. 
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Current evidence shows that many regions use secondary and tertiary care to manage low back pain. 
Globally, individuals with low back pain present to emergency or medical specialists, which are high 
cost; low back pain should be managed first in primary care for patient seeking care. Finally, public 
health is not adequately engaged in prevention of low back pain disability (Figure 1 A). 
The expectations of implementing evidence-based recommendations for low back pain are that; the 
public health sector will be more engaged by providing public health education and exercise, the access 
to spine care will be enhanced, early care for low back pain will be evidence-based, while care will be 
a continuum and patient centered to prevent disability (Figure 1B).  
 
Figure 1A. Depicts current low back pain care in many countries where access to care is available. 
Figure 1B Depicts optimizing spine care based on evidence to prevent disability.  
Adapted from Johnson CD et al, The Global Spine Care Initiative: model of care and implementation. European 
Spine Journal 2018 27 (Suppl 6): S925-S945 [43] 
The current evidence for public health initiatives are that exercise and education in combination have a 
moderate effect on the prevention of disability for low back pain [7, 44, 45]. 
Guidelines developed for high income settings were adapted by the Global Spine Care Initiative and the 
Lancet Back Pain Series to serve communities in low- and middle-income communities by considering 
factors such as costs and feasibility, benefits, harms as well as the quality of underlying evidence [7, 
44]. It is important to adapt treatment to cultural availability, cost of interventions acceptability in the 
community and patient preference.   
Treatment options for low back pain based on evidence for acute (< 3 months) and chronic (> 3 months) 
are depicted in Figure 2. These guidelines also point out the importance to involve the community and 
the use of a bio-psychosocial framework. The efficacy of these treatment is small to moderate. 
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Figure 2: Evidence treatment for low back pain based on guidelines and systematic reviews.  
Adapted from Chou R et al: The Global Spine Care Initiative: applying evidence-based guidelines on the non-
invasive treatment on back and neck pain in low- and middle-income communities. European Spine Journal (2018) 
27 (Suppl 6): S851-S860 [44] 
 
It is hoped that these recommendations will be adopted by the primary healthcare providers and thereby 
reduce disability from non-serious low back pain.  
Future consideration 
Musculoskeletal impairment and disability are increasing due to the aging population and lack of access 
to evidence-based care. Low back pain is a source of worry for the low- and middle-income 
communities. The recommendations to shift the responsibility to primary healthcare providers and to 
base treatment options on evidence can only yield positive results for the individual seeking care for low 
back pain. The massive effort of the World Health Organization for low back pain is commendable and 
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6.3 Joint pain (OA) management – NSAIDs to self-management  
Michael V. Hurley 
 
 
Chronic joint pain in older people, usually labelled osteoarthritis (OA), impact all aspects of people’s 
personal, social and working lives, resulting in enormous health and social care expenditure [46, 47], 
that are increasing rapidly [48, 49]. Despite its prevalence joint pain is managed poorly. Current care 
pathways can be unnecessarily complicated, costly, inefficient, disjointed and delay, even prevent, 
people accessing appropriate, timely treatment [50-53]. Management guidelines recommend exercise 
and maintaining healthy body weight as cost-effective ways to improve pain, mobility, physical and 
mental wellbeing [50-56]. Unfortunately, GPs receive little training in promoting and supporting 
lifestyle changes, and these cannot be conveyed in a 12-minute consultation [52, 57, 58]. Most people 
are maintained on long-term analgesia, despite this having limited effectiveness, unpopular [59], 
expensive [60] and risks serious side-effects [61-63], and joint replacement has limited availability and 
is contra-indicated in many older people. Few people receive advice about self-management and 
importance of participating in regular physical activity and maintaining a healthy body weight. 
This has led to new ways of delivering high quality effective, efficient care [64, 65] for people with 
uncomplicated musculoskeletal conditions [66-68], by-passing the delay and cost of unnecessary 
primary or secondary care physician referral, instead led by allied healthcare and other professionals 
[59, 66, 69, 70]. These include telephone helplines [71], specialist help in primary care and first contact 
practitioners [72-74], patient initiated appointments [75] and self-referral to physiotherapy [76]. Such 
innovative schemes can improve timely access to more appropriate management. 
Once in the system effective, rehabilitation programmes based on the “biopsychosocial model” of 
healthcare can help people appreciate what they can (not) and what they should (not) do for themselves, 
promoting active self-management. Biopsychosocial healthcare considers ill-health to be a complex 
interaction of the physiological, psychological and socioeconomic sequelae of health problems [77-79]. 
It places great importance on the influence of people’s health beliefs, experiences, emotions, social 
networks and external environment on their reaction to ill-health and subsequent behaviour. It compels 
us to deliver health care that address people’s holistic needs, to help them understand why and how they 
can manage their problems, by adopting lifestyles that minimise its affects and maximise their ability. 
Effective rehabilitation programmes of this type exist. Enabling Self-management and Coping with 
Arthritic Pain using Exercise (ESCAPE-pain) [80-82] and Joint Pain Advice (JPA) [66, 70]  integrate 
information-giving, advice, support to change behaviours and exercise participation. They help people 
understand their problem better, dispel erroneous health beliefs, advise them what (not) to do and 
experience the benefits of exercise on their physical, mental and emotional wellbeing. Participants learn 
that adopting healthy lifestyles (physical activity, weight control) are self-management strategies they 
can use to control their symptoms. They become more self-reliant, confident, positive and optimistic. 
Such programmes are more effective, efficient and sustainable ways of helping the large numbers of 
people help themselves to control chronic joint pain. 
Unfortunately, such programmes have traditionally been delivered by healthcare professionals in 
healthcare facilities. Given the logistic and financial constraints of healthcare systems, seriously limit 
the number of people that can be “reached” and benefit. Moreover, without sustained support, people 
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stop exercising and short-term improvements are lost. Long-term support cannot be provided by 
healthcare systems. Other ways of maintaining adherence to regular exercise need to be established in 
order to sustain its benefits. 
To address these limitations, we have delivered ESCAPE-pain in leisure and community venues led by 
exercise professionals, avoiding the need for limited, costly healthcare facilities and professionals. In 
addition, this de-medicalises joint pain that people accept as a normal part of life and ageing, they get 
used to attending non-medical establishments and community organisation that can put in place 
additional ways to support people in their local community after completing the programme. 
Consequently, healthcare commissioners are now commissioning ESCAPE-pain outside hospitals led 
by other professional groups. 
Similarly, JPA can be delivered by a range of professionals (clinicians, health trainers, social prescribers, 
community pharmacists, occupational health), in a range of clinical and community settings [66, 70]. It 
may be particularly useful delivered in workplace settings to address the enormous problem of lost 
productivity, presenteeism and absenteeism caused by chronic knee, hip and back pain. 
Interventions like ESCAPE-pain and JPA require people to attend healthcare or community facilities. 
This precludes people if an intervention is not running near them, and in rural, isolated communities. 
The recent Coronavirus pandemic brought these issues into much sharper focus and more important. 
COVD-19 disproportionately affected older people who were forced to socially isolate, exposing them 
to the consequences of prolonged inactivity and social isolation and group interventions were prohibited. 
We worked with clinicians and exercise professionals to adapt ESCAPE-pain so that some centres 
delivered the programmes online. Feedback has been mixed. Some centres successfully recruited people 
and delivered “online-programme”. Others have reported difficulties with recruitment, technical 
problems (equipment, no/poor reception), issues for disadvantaged groups (language, technical 
understanding and ability and access, social deprivation, cognitive impairment in the elderly). It is not 
always a cheaper option as providers still need to provide a room or studio to deliver from, facilitator’s 
time, technical equipment and support. Moreover, we do not know if the virtual programme is as 
effective as the face-to-face programme, which enables participants to socialise with their peers and is 
considered vital to it’s success. However, the success of some centres demonstrates these types of 
interventions can be delivered online, and could enable people currently excluded to access the 
programme. Although there are many challenges, online/remote/virtual/tele-interventions are likely to 
become more common. 
To help the already large and increasing number of people with joint pain who require help, advice and 
on-going support, we need to rethink and redesign the way we deliver effective care. This can be 
achieved if we utilise a range of professionals to deliver evidence-based programmes that deliver 
information, advice, supported self-management and exercise, and help them sustain the benefits in their 
local communities. This would revolutionise care of people with joint pain, making it better, more 
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Orthopaedic surgery including traumatology has developed dramatically during the last decades. Most 
departments have developed into very efficient units with short lengths of stay. Day surgery for hip and 
knee arthroplasties is routine in many clinics. Moreover, new technologies have emerged, giving more 
possibilities for patient treatment. The volume of new information, scientific publications and new 
technology are increasing rapidly. This challenges the orthopaedic surgeon, both in selecting the right 
treatment for each patient and especially the evidence for applying that treatment. Several other 
challenges will emerge in the future, including an increased demand for health care services, the reason 
that a change in practice may be required. Moreover, diversity is warranted in orthopaedic surgery and 
traumatology. 
Increasing demand for health care service 
In many parts of the world the elderly population will expand due to the greying of the baby boomers 
and to longer life expectancies.  It is estimated that a variety of surgical procedures within degenerative 
joint diseases of spine, hips and knees will increase significantly. Forecasts indicate increasing numbers 
of total knee replacements; depending on forecast model, increases of 143% and up 855% in volume are 
projected in 2050 compared to 2012 [83]. 
This increase is explained partly by more elderly people, but also, change in indication for surgery as 
shown by registry data - especially in the younger age groups and in the 90+ age group. In trauma, the 
number of proximal femoral fractures is expected to increase by a factor of 2-3 particularly in Asia [84]. 
Although a small decrease in age and sex specific incidence has been identified in some countries, this 
may not have any significance on the total numbers world-wide. 
In contrast to osteoarthritis and traumatology, surgical treatment of patients with rheumatoid arthritis 
within the area of total knee (TKA) and hip arthroplasties (THA) has decreased during the last decades 
and this trend is expected to continue [85].  
Stakeholders demand 
Patients are becoming more demanding, expecting high activity level and better quality of life for a 
longer time period than ever before. Hence there is a societal demand to do something, and often a joint 
replacement. This may also play a role in the demand for short waiting lists which, will in turn increase 
the demand for surgery. Thus, there is a need for change in practice, in order to keep up with an otherwise 
increasing demand, since every surgical procedure has a risk of complication and the health care system 
has a limited capacity. 
Change in practice 
Non-surgical treatment. In recent years, the focus has been on effect of non-surgical treatments for 
degenerative joint diseases but also patients with fractures. There is evidence that training may play a 
role in treatment of more early stage knee osteoarthritis [86]. A more systematic approach may delay 
the need for a surgical procedure and in the future should be applied before surgery is considered.  
Regarding trauma cases, proximal humerus and clavicle fractures have successfully been treated non-
surgically which has in part, changed practice [87].  
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At present, there seems to be no pharmaceutical treatment of degenerative diseases, but if or when this 
changes, it will revolutionize the health care system and treatment of patients suffering from 
osteoarthritis. 
 
Shorter stay in hospital.  Same-day discharges following THA and TKA have become feasible during 
recent years. It is reported to be safe in selected cases, especially in patients younger than 80 years not 
living alone. There is a need for education of patients and health care providers to make a success of 
this. Shorter stay in hospital within other patient groups is also needed - for better treatment of the 
patients but also because hospitals of the future are built with fewer beds. 
 
Specialisation. Orthopaedic surgery is specialized into trauma, hand, shoulder-elbow, spine, hip, knee, 
foot and ankle, infection, tumour surgery and sports. In many countries, specialisation means that the 
majority of surgeons do only one or two sub-specialities.  This trend had the aim of increasing treatment 
quality. Specialisation has been one of the drivers in moving towards more patient-specific treatment, 
such as patient-specific implants.  
More possibilities are emerging. These will encourage surgeons to try new techniques in the future 
which will challenge the health care system, as they are likely be much more expensive. Robotic surgery 
may emerge, similarly custom made implants and 3D printing for surgical planning; and there is a need 
to validate these new techniques before taking them into routine practice. As in many other specialties, 
artificial intelligence and machine learning may develop within orthopaedics,  with a good basis for this 
due to the existence of many big databases, for example joint replacement. 
Diversity 
There is also a need for diversity and harmonisation, including attracting all genders to the orthopaedic 
speciality. More women are needed in orthopaedic surgery, but the specialty has to be attractive to them. 
Diversity is also expressed through variation in treatments. Although that we have the same knowledge 
around the world, there is a large variation in treatments between countries and even between regions in 
countries. This is explained by the existence of few evidenced-based studies to demonstrate which 
techniques or procedures are most effective, such that patients rely on the advice and preference of their 
individual physician and surgeon; leading to discrepancies between practice patterns and utilization. The 
need to harmonize is clear, but may be by challenged by differences in cultures, traditions, and health 
care systems.  
Future perspectives 
To meet future requirements in orthopaedic surgery there is a need for continuous medical education; 
which should ensure basic knowledge to prevent complications, such as infections. Research into 
preventing osteoarthritis and use of non-surgical treatment are of utmost importance, otherwise the 
numbers for surgery will overload capacity. Too long waiting lists are already the scenario in many 
countries. Moreover, the incentive to not perform surgery may be more balanced in the future. The 
payment system, even in public health care systems, encourages surgeons to perform surgery.  
If there is no change in treatment practice, a clear increase in numbers of nurses, physicians and 
surgeons, and the production system itself, will be required to give the same health care service as today. 
Increases in the cost of health care will be evident.  
The need for evidence based treatment may be even more demanded and demanding in future. This is 
to ensure safety, efficient treatment and judicious use of healthcare resources, thus more clinical research 
is warranted. 
  14(32) 
6.5 Post-fracture management – Fracture Liaison Services Taiwan 
 
The fragility fracture care gap in Taiwan and Fracture Liaison Service (FLS) in National Taiwan 
University Hospital healthcare system  
 
 
In the 21st century, osteoporotic fractures have become a serious public health crisis due to rapid 
population aging. Osteoporosis is characterized by decreased bone mass and disrupted bone architecture, 
resulting in increased bone fragility fracture risk [88].  
In Taiwan, the lifetime fracture risk of vertebrae, hip, or wrist is 33% and 20% in women and men, 
respectively. Furthermore, the 1-year mortality rate after hip fracture was 11% and 18% in women and 
men, respectively, in 2009 [89]. However, despite the high burden of fragility fracture, only one-fourth 
hip fracture patients underwent bone mineral density (BMD) assessment [90]. Moreover, only about 
15% of male and one-third of female osteoporosis patients in Taiwan received anti-osteoporosis 
treatments around 10 years ago [91]. Fracture liaison service (FLS), a coordinated program to prevent 
further fractures, has been shown to improve BMD testing rate, medication initiation rate, adherence, 
overall survival, and decrease re-fracture rate significantly [92]. 
In 2014, National Taiwan University Hospital (NTUH) was the first health care institute to establish an 
FLS program in Taiwan. Here, we would use the NTUH model to exemplify the backbone structure of 
FLS programs in Taiwan [93]. 
In this model, newly diagnosed hip fracture patients in orthopedic ward (Group A), unrecognized 
vertebral compression fracture patients from the geriatrics ward, (Group B), and clinic vertebral 
compression fracture patients (Group C) were enrolled from outpatient clinics. (Figure 1) 
 
Figure 1. Flowchart of NTUH FLS program enrollment and interventions [93] 
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Based on this protocol, enrolled cases receive multifaceted evaluation including 10-year fracture risk 
assessment, BMD assessment, fall risk assessment when appropriate, lifestyle evaluation, and laboratory 
tests for secondary causes of osteoporosis. Furthermore, if the patient has been receiving medication for 
osteoporosis, the reviews for side effects, dosage, interaction, compliance, and contraindications were 
incorporated. Medications were initiated or modified after assessment. Regular telephone follow-ups 
and frequent communications between care coordinators and patients were provided.   
 
FLS network development in Taiwan 
Since 2014, the number of new FLS programs has grown rapidly across Taiwan, and these programs 
now cover osteoporosis patients nationwide. The Taiwan Osteoporosis Association (TOA) has hosted 
multiple workshops to facilitate the establishment FLS in the national scale from 2016. Furthermore, 
the TOA encourages health care institutions to apply for Best Practice recognition from International 
Osteoporosis Foundation (IOF). As of March 2020, 21 FLS programs accredited on the Map of Best 
Practice as gold (5), silver (9), bronze (3), under review (1), and in progress (3), were included on the 
Capture the Fracture (CtF) website (http://capturethefracture.org/map-of-best-practice) [94]. (Figure 2)  
Since some cultural aspects were not well addressed in the original Best Practice Framework, some of 
the framework components might be difficult to implement in the Asia-Pacific region. Therefore, the 
TOA gathered domestic and international experts to develop the “Consensus on Fracture Liaison Service 
Best Practice Standard in the Asia-Pacific Region” in 2017 to modify the guideline to be more applicable 
in the AP region [95]. The TOA was awarded the Best Secondary Fracture Prevention Promotion at the 
2017 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCOESCO) held 
in Florence. In 2019, TOA was also granted the best World Osteoporosis Day Campaign at the 
WCOESCO for FLS promotions. Taiwan may have one of the highest densities of FLS programs in the 
AP region, considering the population size (approximately 23.6 million in 2019) [96]. 
Field Code Changed




programs established in Taiwan until March 2020. 
 
FLS outcome from Taiwan experience 
In the NTUH FLS program, Chao et al. have demonstrated that among FLS participants, advanced age 
and comorbidities (e.g. chronic kidney disease, heart and neurologic disease, cancer, osteoarthritis, and 
diabetes) predicted a lower probability of short-term recovery, worse 2-year survival rate, and a higher 
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risk of falls [97, 98]. On the other hand, markers of good nutrition, such as higher body mass index and 
serum albumin levels, correlated with lower mortality. If the patient has comorbidities affecting dietary 
protein intake (e.g. in chronic kidney disease patients), nutrition is an even more crucial factor and 
should be suitably addressed. 
 
Conclusion 
The development of FLS in Taiwan is still dynamic and the coordinated care model has been shown 
to benefit patients in the long term. The sustainability and distribution of the FLS program can be further 
improved if the programs are incorporated into National Health Insurance system and provide aid to 
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Changes in the management and outcome of Rheumatoid Arthritis 
Rheumatoid arthritis has changed.  40 years ago, it was a chronic, progressive disabling disease with 
significant systemic features and no effective treatments that significantly modified the outcome.  It was 
characterised by a variety of extra-articular manifestations such as weight loss, chronic anaemia, 
rheumatoid nodules, sicca syndrome, amyloid and vasculitis including indolent leg ulcers. Cervical 
myelopathy was seen due to atlanto-axial subluxation resulting from joint damage.  Significant disability 
was considered inevitable, and there was increased mortality related to the various extra-articular 
manifestations and increased risk of infections.  Although there were a range of disease-modifying anti-
rheumatic drugs (DMARDs) in use there was little evidence that they changed the long-term course of 
disease and they were often used late and sequentially for limited periods of time because of side effects 
or lack of efficacy.  Now it is a disease that can be effectively controlled in many people and, if from an 
early stage, it has a limited impact with people able to participate in the activities they want to and need 
to.  Many extra-articular manifestations are seldom seen.  This has come about not from changes in the 
epidemiology or pathogenesis of the disease but from better therapeutic agents based on a scientific 
understanding of the molecular and regulatory mechanisms of the disease, its epidemiology and much 
improved strategies for how to use these treatments.  This has been supported by the development of 
better measures of disease activity and measures of disease impact that are relevant to people with 
rheumatoid arthritis. 
In 1997, when this publication first considered early rheumatoid arthritis [99], joint damage was often 
already evident at diagnosis which was usually late.  Disease activity was monitored but inconsistently 
with no clear strategy.  The aim was to learn how to identify those with a poor prognosis and then treat 
aggressively, with the benefit of methotrexate having been shown to be an effective disease modifying 
agent.  Various early arthritis cohorts were followed to understand prognostic factors [100, 101] and to 
investigate the aggressive use of combination therapies.  The ability to perform large multicentre studies 
such as the COBRA study [102], along with the benefit of better ways of assessing disease activity and 
the outcome both in terms of radiographic damage and function [103] not only identified effective 
interventions but also led to a better understanding of how to use them to most effect.  The scientific 
community committed itself to make rheumatoid arthritis a curable or at least a suppressible disease 
rather than accepting just trying to modify it.  The use of the term ‘disease modifying drugs’ reflected 
the lack of ambition. 
Having more effective interventions has been pivotal.  As the pathophysiology of rheumatoid arthritis 
was becoming more clearly defined, biotechnological advances were putting forward candidate biologic 
interventions which were investigated in animal models followed by clinical trials which in the 1990’s 
were beginning to show exciting data for monoclonal antibodies against anti TNFα [104].  Methotrexate 
was shown to be effective at reducing disease activity in the 1980s [105] and soon found to be more 
effective and better tolerated enabling longer term use in the 1990s resulting in improved long-term 
outcomes.  The addition of a range of very effective biologic agents has greatly increased therapeutic 
options which are widely available, although access is limited by cost.  
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Knowing how to use these new effective agents is equally important and the early arthritis cohort studies 
showed it was difficult to predict with any certainty who would do well and who would do badly.  This 
led to the thinking of treating everyone with the disease as early as possible.  The concept of inverting 
the pyramid and treating aggressively with combination therapies as early as possible came from studies 
such a COBRA – a large multicentre long-term study with multiple treatment arms [102].  If the goal 
was to suppress the disease, then measures were needed to evaluate this.  Previously the aim was to 
make people better but the change in ambition was to make them good and aim for remission [106]. 
This was supported by the standardisation of endpoint measures for clinical trials by OMERACT [107], 
the European League Against Rheumatism (EULAR) and the American College of Rheumatology 
(ACR) and gaining general support through the community working together.   The development of an 
absolute measure of disease activity - the DAS (Disease Assessment Score) and response criteria [103] 
supported the development of the strategy of treating to a target [108] to achieve remission.  A patient 
centred approach has long been taken in the management of rheumatoid arthritis considering function, 
with the development of AIMS [109, 110] and these measures have been further refined with the focus 
on patient relevant outcome measures [111].  
 
A strategy to treat early and aggressively to achieve a target of remission faced the barrier of the early 
diagnosis and a different approach to diagnostic criteria changed thinking to the early identification of 
those with a probability of a poor outcome with new EULAR / ACR diagnostic criteria [112].  This was 
supported by identifying anti-cyclic citrullinated peptide (anti-CCP) as an early indicator of poor 
prognosis [113] and the use of ultrasound to identify synovitis [114]. 
Embedding such changes in everyday clinical practice is a challenge, with novel therapeutic agents but 
also different ways of using them.  There are also implications for how care is delivered, with the move 
to early diagnosis and close monitoring of disease activity.   It was recognised in 1997 that changing 
practice in the management of RA needed to be supported by guidelines that provided explicit 
recommendations on the most effective management in the light of scientific evidence [108]. This 
matched the new focus on evidence-based medicine and also the need to be demonstrate the cost-
effectiveness of any treatment strategy if one wants it to be implemented by healthcare systems, with 
the development of quality-adjusted life years to enable the impact of different diseases to be compared.    
In all these advances, a global collaborative approach by the whole rheumatology community – 
clinicians, clinical researchers, scientists and people with personal experience of RA – has been a 
powerful driver. 
Although disease activity and outcomes have been shown to be different in populations around the world 
related to availability and access to treatments [115] with a relationship to national gross domestic 
product [116], overall there has been an improvement of outcomes across the globe.  However, these 
differences highlight key issues of availability, accessibility, affordability - all key components of 
universal health coverage [117]. Important factors are ensuring people are diagnosed early and have 
timely access to appropriate management.  This means getting timely access to the right level of 
competency within the healthcare system which is a barrier in many countries.  It also needs a change 
in expectation of people with rheumatoid arthritis and for them to seek appropriate care at the onset of 
their symptoms to achieve remission – an important role for advocacy and public education. 
Changes in services for the management and support of people with RA 
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The changes in the management of RA and in the co-morbidities and disability now seen along with 
changed expectations of healthcare has consequences for how health care systems provide care at the 
micro and meso level as well as what is required at the policy level, both now and in the future. 
Previously, chronic disabling nature of RA with extra-articular features and associated with major long-
term physical disability but without effective treatments resulted in a multidisciplinary palliative and 
rehabilitative approach to manage the disease and its consequences, along with a therapeutic approach 
in an attempt to control it.  This brought together rheumatologists, physiotherapists, occupational 
therapists with the support of orthopaedic surgeons, podiatrists and other specialties to help manage 
extra-articular manifestations.  Rheumatologists were involved in the rehabilitation of patients along 
with disease management and care was often in-patient based.  Supporting people with RA and helping 
them help themselves has long been a priority, with education, self-management programmes and the 
third sector providing information and support.  Specialist nurses to educate support patients were 
introduced and the expert patient programmes were first developed to enable people with RA to self-
manage [118].  People with RA clearly stated what they expected from health care systems to support 
them [119]. Person-centred integrated care and shared decision making has long been embedded in care 
pathways.  What service was needed to deliver this in Europe was defined [120]. 
 
With the focus on achieving remission and the reduction in disease-related joint damage, few severe 
extra-articular manifestations and reduced impact on individuals when disease control or remission is 
achieved, the services needed and how they are delivered have changed.  The focus is on monitoring 
disease activity and adjusting treatment as needed.  This can be done in ambulatory care with 
possibilities of remote monitoring and there are few dedicated inpatient facilities.  This is along with 
general changes in how long-term conditions are managed, and there are now few dedicated in-patient 
rheumatology facilities.  The need for rehabilitation and joint replacement surgery is also less, but there 
is a greater need for education and support to enable the person to actively participate in the management 
of their disease.  It is more challenging to take an integrated approach if the team is not working together 
in a hospital facility and specialist rheumatology nurses provide the anchor for people with RA in some 
countries with a major role in patient education and are often supporting disease management through 
monitoring disease activity.  The third sector remains and important source of information and support 
but done largely through help lines and the internet, rather than face-to-face support groups.   
The needs of people with RA have not changed, however. Although it can be better controlled, there is 
not a cure and many people still have limits on their participation in everyday life, including work [121]. 
The standards of care for what people with RA should expect to receive and health-care quality 
indicators that measure whether the health services are delivering them have been established in Europe 
to improve access to appropriate care and outcomes [122, 123] and still identify the need for treatment, 
pain management and rehabilitation. 
The change in delivery of health care at the present time in response to the Covid pandemic has 
accelerated the introduction of e-health and remote monitoring and support of people with RA and few 
face-to-face interactions.  This may be an advance, but some aspects of care and support may be missed 
and it may increase inequalities of care and outcome.  This needs to be carefully evaluated. 
 
What is needed to deliver current strategies for the management of Rheumatoid Arthritis 
Health systems need to deliver the most cost-effective strategies that also meet the needs and wishes of 
people with RA.  There is greater awareness by many of what can be achieved.  Cure is the ultimate 
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goal but achieving remission is a realistic target for many if diagnosed early before irreversible damage 
has occurred.   
Any health system must therefore enable early diagnosis; treatment to target; support people’s active 
participation in their care; manage any co-morbidities; and meet their functional expectations and needs 
including enabling to stay in work.  There are health-care quality indicators developed in Europe [122] 
that reflect what should be provided and achieved.  This needs a workforce fit for purpose taking a 
person-centred integrated approach as well as equitable access to modern therapeutic agents.  With the 
challenges of greatly different resources, both economic and human, between high-, middle- and low-
income countries, the improved opportunities and outcomes for many also exacerbate the disparities that 
exist and need to be addressed through ensuring universal health coverage includes equitable access to 
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6.7 Delivery of health care – innovative models and e-health  
 
Leif E Dahlberg, Håkan Nero 
 
 
Traditionally, health care is delivered by a number of face-to-face meetings to obtain patient history and 
perform examinations to finally establish a diagnosis and eventually start treatment. This praxis, in spite 
of seeming rational by patients and health care professionals, needs to be reconsidered in light of 
shrinking healthcare resources combined with increasing needs and public demands. 
Chronic diseases use some 80% of healthcare resources and half of the population in the western world 
has at least one chronic condition. The need for continuous and frequent treatment to handle chronic 
conditions, not the least during pandemic conditions when unnecessary exposure to the virus should be 
avoided, makes it obvious that the present way of delivering health care is not compatible with future 
needs and demands. 
The question is whether it is possible to establish a diagnosis, in order to start treatment, by other means 
while still reaching similar outcomes, treatment risks and costs. We suggest that it is a myth, related to 
old tradition and routine, that a face-to-face meeting is always necessary. The patients are well aware of 
their body symptoms and can, most of the time, give conclusive answers to correct questions. Still, it is 
always possible in situations of uncertainty, to see the patient face-to-face in a traditional care setting. 
For example, Teladoc refers 1% of their telehealth patients. With the use of algorithms, patients can be 
optimally triaged even before meeting with any health care professional. 
Telehealth was first developed in areas outside MSK. Studies show significant HbA1c reduction, 
continued weight loss and reduced cardiovascular diseases using privately developed e-health solutions 
in diabetes care [124, 125]. In relation to MSK, several peer reviewed studies are now available on the 
effectiveness of digital delivery of OA management by new e-health technology platforms [126-130].  
Treatments, including management of osteoarthritis of the knee and hip as well as low back pain, show 
clinically relevant improvements in pain and function. The most costly procedure of osteoarthritis of the 
knee and hip is total joint replacement. A notable finding with respect to osteoarthritis of the knee and 
hip is that after continuous participation in a telehealth program, patients decrease their willingness for 
surgery.  
Another issue to consider is that, regardless of how relevant and adequate the information in the 
telehealth solution, to be used it needs to be appreciated by the users. In this respect the authors can 
provide information from a Swedish treatment platform for OA. This digital solution is an application 
available in iOS and android. Qualitative studies support that patients find the application beneficial and 
easy to use. It has been developed in close relationship to the users, in order to fulfill expectations from 
the patients and physiotherapists. One of the databases also shows a NPS of 55 which is considered very 
high (Net Promoter Score (-100-+100) is calculated by subtracting the percentage of customers who 
answer the NPS question (0-10) with a 6 or lower (known as ‘detractors’) from the percentage of 
customers who answer with a 9 or 10 (known as ‘promoters’) [128]. Questionnaires answered by the 
physiotherapists using the application show that they find the application easy to use and that they can 
handle patients more efficiently. Finally, patients rate their support by the physiotherapists 4.5 on a scale 
of 1-5. 
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Besides the possibility of reaching a high level of satisfaction if the digital application is designed in a 
patient friendly manner, by using telehealth there is no need for transportation to a facility, and treatment 
can thereby be done whenever it fits into each patient's schedule. Notably, remote locations around the 
globe can equally access telehealth. Likely explanations for the impressive results of some of these 
digital platforms is the ease of access to individualized treatment, engagement, support  and nudging 
from a licensed healthcare professional, together with high daily treatment adherence facilitated by the 
digital nature of the program.   
 
In conclusion, most patients with MSK conditions can be diagnosed and treated by a telehealth solution. 
With results that are similar or better compared to traditional care, seemingly without risk and at a lower 
cost, this suggests that telehealth will grow exponentially in the coming years; not least since people 
will most likely seek to continue using these services even after the pandemic subsides. Further 
confirmation is to be presented in future studies. 
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6.8 Discussion 
  
Advances in delivery of health care for MSK conditions has been extraordinary, for some conditions, 
over the past decades, whereas for others much more is needed as this chapter highlights. 
Musculoskeletal pain is still one of the greatest challenges, reducing the quality of life for those affected 
whether from back pain, joint pain or from other regions of the musculoskeletal system. Encouraging 
inroads to improved management are, however, on their way. Surgical and technological advances are 
closely linked with advances in other areas of medicine; allowing surgical intervention at much greater 
ages, leading to greater independence and mobility. This is true both for degenerative conditions and 
fracture treatment. Better treated fractures, particularly fragility fractures, requires appropriate post-
fracture care to reduce the risk of recurrence, a serious threat to better health in the older person. The 
paramount advances in management and treatment of RA has vastly reduced the need for surgical 
procedures, with biological treatments contributing to a huge shift and the possibility for remission in 
an otherwise potentially severely disabling condition.  
Delivery of medical care has changed rapidly during the past year with the Covid-19 pandemic and 
changes, that otherwise would take years if not decades, have been introduced rapidly. Digital patient 
visits and other digital modes of delivering care are likely to be a normal part of future medicine. 
 
Practice Points 
- Standardized care pathways focusing on the individual are the most patient-, system- 
and cost-effective mode of delivering high value care, whether pharmacological, 
surgical or preventive. 
 
- Standardized care pathways require an integrated multi-professional approach; 
everyone around the table has the same aim – what will be best for the patient(s). 
 
- New management models and treatment modalities, including new technology, 
requires appropriate evaluation prior to implementation, through standardized health 
technology assessment. 
 
- New management models must consider all ages, all cultures, all economies in 
addition to available competencies to ensure the best possible access and outcome 




- Systematically collected real-world data is needed to demonstrate effectiveness from 
any new ways of delivering care. 
 
- Studies of patient-perception on new ways of delivering care will be essential for 
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